Alexandre J. Maria
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer.
Journal: ESMO open
Published: October 17, 2025
Checkpoint inhibitor effectiveness after corticosteroids and second-line immunosuppressants for immune-related adverse events in non-small-cell lung cancer.
Journal: ESMO open
Published: October 17, 2025
Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus following pembrolizumab therapy.
Journal: JAAD case reports
Published: September 08, 2025
Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case series.
Journal: Cancer immunology, immunotherapy : CII
Published: September 07, 2025
Evaluation of the mycophenolate mofetil-rituximab combination in systemic sclerosis: a French retrospective multicenter study (MycRiSSc).
Journal: Journal of autoimmunity
Published: September 03, 2025
Plasma exchange as potential treatment of severe immune checkpoint inhibitor-induced hepatitis.
Journal: JHEP reports : innovation in hepatology
Published: August 09, 2025
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: May 13, 2025
Immune checkpoint inhibitor-related eosinophilic fasciitis: 3 case reports with literature review.
Journal: La Revue de medecine interne
Published: January 29, 2025
Misdiagnosis of Hodgkin disease as histiocytosis is associated with adverse consequences.
Journal: Journal of hematopathology
Published: June 11, 2024
Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients.
Journal: RMD open
Published: May 27, 2024
Last Updated: 09/26/2026